Progress in the pharmacotherapy of uveitis: the art of personalized care

References

• Foster CS, Kothari S, Anesi SD, et al. The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61(1):1–17.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Bodaghi B, and Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49(3):438–445.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Neri P, Deuter C. New pharmacotherapy options for noninfectious posterior uveitis. Int Ophthalmol. 2021;41(6):2265–2281.
   PubMed Web of Science ®Google Scholar
• Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology. 2014;121:365–376.
   PubMed Web of Science ®Google Scholar
• Gamalero L, Simonini G, Ferrara G, et al. Evidence-based treatment for uveitis. Isr Med Assoc J. 2019;21(7):475–479.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 2013;156(2):228–236.
   PubMed Web of Science ®Google Scholar
• Feiler DL, Srivastava SK, Pichi F, et al. Resolution of noninfectious uveitic cystoid macular edema with topical difluprednate. Retina. 2017;37(5):844–850.
   PubMed Web of Science ®Google Scholar
• Ferreira LB, Farrall AL, Furtado JM, et al. Treatment of noninfectious uveitis. Arq Bras Oftalmol. 2021;84(6):610–621.
   PubMed Web of Science ®Google Scholar
• Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010;18(2):116–120.
   PubMed Web of Science ®Google Scholar
• Lee DH, Daud U, Wipfl J, et al. The decreasing prevalence of uveitis associated with juvenile rheumatoid arthritis: do NSAIDs play a role? J Clin Rheumatol. 2003;9(3):151–155.
   PubMed Web of Science ®Google Scholar
• Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010;11(7):1135–1146.
   PubMed Web of Science ®Google Scholar
• Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916 e1911–1917.
   Web of Science ®Google Scholar
• Steeples LR, Anand N, Moraji J, et al. Clinical outcomes of intravitreal preservative-free triamcinolone preparation (Triesence(R)) for cystoid macular oedema and inflammation in patients with uveitis. Ocul Immunol Inflamm. 2018;26(7):997–1004.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553.
   PubMed Web of Science ®Google Scholar
• Karti O, Saatci AO. Intravitreal dexamethasone implant in the treatment of non-infectious uveitic macular edema. Med Hypothesis Discov Innov Ophthalmol. 2018;7(4):169–175. PMID: 30505868; PMCID: PMC6229676.
   PubMedGoogle Scholar
• Bratton ML, He YG, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS. 2014;18(2):110–113.
   PubMed Web of Science ®Google Scholar
• Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (OZURDEX((R))) for macular edema secondary to noninfectious uveitis: a review of the literature. Ther Deliv. 2019;10:343–351.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al., Fluocinolone Acetonide Uveitis Study, G.Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–1027.
   PubMed Web of Science ®Google Scholar
• Writing Committee for the Multicenter Uveitis Steroid Treatment T, Kempen JH, Altaweel MM, et al.; . Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317:1993–2005.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–507.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals E. Safety and efficacy study of a Fluocinolone Acetonide Intravitreal (FAI) insert in subjects with chronic non-infectious posterior uveitis. 2021.
   Google Scholar
• Thorne JE, Sugar EA, Holbrook JT, et al; Multicenter Uveitis Steroid Treatment Trial Research, G. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019;126(2):283–295.
   PubMed Web of Science ®Google Scholar
• Edelhauser HF, Patel S, Meschter C, et al. Suprachoroidal microinjection delivers triamcinolone acetonide to therapeutically-relevant posterior ocular structures and limits exposure in the anterior segment. Invest Ophthalmol Vis Sci. 2013;54:5063.
   Web of Science ®Google Scholar
• Edelhauser HF, Verhoeven R, Burke B, et al. Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space. Invest Ophthalmol Vis Sci. 2014;55. DOI:10.1167/iovs.13-13026
   PubMed Web of Science ®Google Scholar
• Chen M, Li X, Liu J, et al. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015;203:109–117.
   PubMed Web of Science ®Google Scholar
• Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of Suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948–955.
   PubMed Web of Science ®Google Scholar
• National Eye Institute (NEI). Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT). ClinicalTrials.gov identifier: NCT02623426. Updated April 1, 2022. Accessed 2022 Jun 1. https://clinicaltrials.gov/ct2/show/NCT02623426
   Google Scholar
• Vegas-Revenga N, Martín-Varillas JL, Calvo-Río V, et al. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. Clin Exp Rheumatol. 2022Jan;40(1):142–149. PMID: 33666160.
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Banker A, and Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina. 2013Nov-Dec;33(10):2149–2154. PMID: 23615343.
   PubMed Web of Science ®Google Scholar
• Merrill PT, Clark WL, Banker AS, et al.; Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Study Group. Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) program. Ophthalmology. 2020 Oct;127(10):1405–1415. Epub 2020 Apr 3. PMID: 32564920.
   PubMed Web of Science ®Google Scholar
• Duica I, Voinea LM, Mitulescu C, et al. The use of biologic therapies in uveitis. Rom J Ophthalmol. 2018;61(2):105–113.
   Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481–486.
   PubMed Web of Science ®Google Scholar
• Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum. 2015Dec;453:361–368. PMID: 26092330.
   PubMed Web of Science ®Google Scholar
• Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87(7):925.
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248–3252.
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2006;66(4):548–550.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447–2451.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912.
   PubMedGoogle Scholar
• Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113(2):308–314.
   PubMed Web of Science ®Google Scholar
• Yalcindag N, Kose HC. Comparison of the treatment results for behcet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm. 2020;28(2):305–314.
   PubMed Web of Science ®Google Scholar
• Ashkenazy N, Saboo US, Abraham A, et al. Successful treatment with infliximab after Adalimumab failure in pediatric noninfectious uveitis. J AAPOS. 2019;23(3):151 e151–151 e155.
   Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, et al. Infliximab and Adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20(1):18–26.
   PubMed Web of Science ®Google Scholar
• Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45:1167–1172.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between Adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adan A, Brezin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Beltran E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223–2231.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martín‐Varillas JL, Calvo‐Río V, et al., Comparative study of infliximab versus Adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 71(12): 2081–2089. 2019.
   PubMed Web of Science ®Google Scholar
• Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology. 2018 Sep;125(9):1444–1451.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rosenbaum JT, Landewe R, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838–844.
   PubMed Web of Science ®Google Scholar
• Sharon Y, Chu DS. Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis. Am J Ophthalmol Case Rep. 2020;18:100633.
   PubMedGoogle Scholar
• Moisseiev E, Shulman S. Certolizumab-induced uveitis: a case report and review of the literature. Case Rep Ophthalmol. 2014;5(1):54–59.
   PubMedGoogle Scholar
• Jabs DA. Immunosuppression for the Uveitides. Ophthalmology. 2018;125(2):193–202.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al., Group,A.T.M. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2(1):4.
   PubMedGoogle Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018May1;57(5):856–864. PMID: 29471416.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019 Apr;200:85–94. PMID: 30660771
   PubMed Web of Science ®Google Scholar
• Heissigerova J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: the phase 2 saturn study. Ophthalmology. 2019;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol. 2012;51:98–109.
   PubMedGoogle Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786.
   PubMed Web of Science ®Google Scholar
• Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm. 2006;14(6):367–374.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014 Apr;22(2): 90–95. PMID: 24143896. Epub 2013 Oct 21. Erratum in: Ocul Immunol Inflamm. 2015 Jun;23(3):266
   PubMed Web of Science ®Google Scholar
• Lopalco G, Schiraldi S, Venerito V, et al. Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. Mult Scler Relat Disord. 2020Jul; 42: 102152. Epub 2020 May 3. PMID: 32408154.
   PubMed Web of Science ®Google Scholar
• Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience. Front Pediatr. 2022Apr12;10:851453. PMID: 35498797; PMCID: PMC9039300.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, Adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021Oct9;22(1):689. PMID: 34627340; PMCID: PMC8502273.
   PubMed Web of Science ®Google Scholar
• Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234. Epub 2019 Jul 3. PMID: 31268748.
   PubMed Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018Dec4;13:53–55. PMID: 30582071; PMCID: PMC6288302.
   PubMedGoogle Scholar
• Kempen JH, Altaweel MM, Drye LT, et al.; Multicenter Uveitis Steroid Treatment Trial Research, G. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122:1967–1975.
   PubMed Web of Science ®Google Scholar
• Buggage R, and Behar-Cohen FF. EYS606 for the treatment of chronic Non-Infectious Uveitis (NIU): results from Part 1 of a First-in-Human (EYS606-CT1) study. Invest Ophthalmol Vis Sci. 2020;61(7):3170.
   Web of Science ®Google Scholar